Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)

xlomafota13 shared this article with you from Inoreader Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):447. doi: 10.3892/etm.2021.9875. Epub 2021 Mar 1. ABSTRACT Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present review discusses the literature on the timing, methods and courses of glucocorticoid treatment for DMD. The review highlights the importance of the immediate commencement of glucocorticoid treatment following the diagnosis of DMD, with weekend-only administration being advantageous. Adherence to long-term single-glucocorticoid therapy can delay the loss of ambulation ability, and the side effects of the treatment are controllable. However, the standard medication for patients of different ages and stages of disease development, and the use of combination t herapy require further investigation. PMID:33777191 | PMC:PMC7967797 | DOI:10.3892/etm.2021.9875 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.